StockData

bioAffinity Technologies vs OmniAb

BIAF and OABI side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BIAF and OABI compare

OmniAb is the larger company, worth 47 times as much as bioAffinity Technologies ($737M against $15.6M).

OmniAb grew revenue faster over the last twelve months (90.6% versus −23.2% for bioAffinity Technologies).

OmniAb keeps more of each dollar of sales as profit, with a net margin of −108% compared with −257% at bioAffinity Technologies.

OmniAb scores higher on the StockData Score (9 against 5 for bioAffinity Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBIAFOABI
Size and price
Market cap$15.6M$737M
Share price$1.93$5.05
Change, 1 year−93.0%224%
Change, 5 years–−49.5%
Beta (5Y)–1.68
Employees57107
StockData Score
Total score59 (better)
Valuation score3 (better)1
Growth score01 (better)
Performance score01 (better)
Health score26 (better)
Dividend score00
Valuation
P/S2.6× (better)18.3×
P/B4.1×3.0× (better)
P/FCF–309×
FCF yield−73.9%0.32% (better)
Fair value$6.61$3.71
Margin of safety70.8% (better)−36.2%
Growth
Revenue growth (TTM)−23.2%90.6% (better)
Profitability
Operating margin−210%−116% (better)
Net margin−257%−108% (better)
FCF margin−196%5.9% (better)
Return on equity−1860%−16.5% (better)
Return on invested capital–−18.3%
Financial health
Debt / equity0.01 (better)0.00
Interest coverage−276.1×–
Current ratio1.444.21 (better)
Altman Z-score−15.859.48 (better)
Piotroski F-score22
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions1.6%42.4%
Held by insiders59.3%5.9%
Insider net buying, 12 months–−$283K

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.